Key facts
- BionicM’s last known valuation is $15.6M (Aug 2024).
- It has raised $13.5M; the latest was Later Stage VC ($510K) in Jan 2025.
- Notable investors include Japan External Trade Organization, Intellectual Property Acceleration Program for Startups, The University of Tokyo Edge Capital, UTokyo Innovation Platform Company, Hong Kong Science & Technology Parks — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for BionicM
- ·The full record, as it builds
Funding rounds
No funding rounds for BionicM are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BionicM
Developer of a robotic prosthesis technology designed to enhance mobility and assist individuals with lower-limb amputations. The company offers a powered knee with motion assist technology that flexes, extends and replaces lost muscle strength and reduces physical burden, enabling amputees to perform daily tasks like standing up, walking, or climbing stairs.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2018
- Employees
- 12
- Website
- bionicm.com/
- Ownership
- Privately Held (backing)
BionicM doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BionicM shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BionicM in its N-PORT filings yet. We sweep new filings monthly.